• ALS Clinical Trials
    • Jan 25, 2016

    The ALS Buzz Around Brainstorm and the Israeli Study

  • View Larger Image

The ALS community looks hopefully at the results of a clinical trial conducted in Israel at Hadassah Medical Center.  The results were published last week in JAMA Neurology, with the paper titled, “Safety and Clinical Effects of Mesenchymal Stem Cells Secreting Neurotrophic Factor Transplantation in Patients With Amyotrophic Lateral Sclerosis – Results of Phase1/2 and 2a Clinical Trials.”  Dr. Dimitrios Karussis, who conducted the clinical trial, was quoted as seeing the results as “very encouraging.”

Bone marrow samples were taken from each of the 26 patients.  In a lab, the bone marrow cells were grown into a type of stem cell that produces NTFs.  These NTFs are nutrients for neuron cells and can have protective effects.  The newly formed stem cells were then injected back into the patients, in their muscles, their spinal cord, or both.  Investigators hoped the neurons would be protected by absorbing the NTFs and less likely to deteriorate and stop functioning, as seen in ALS.  There were some encouraging results that shows this kind of treatment slowed the progression of ALS symptoms.  

So what does it really mean?  There are questions from friends on social media, and news stories showing patients being injected in the spine.  Is this a cure for ALS?

Not yet.  We can be encouraged, but not satisfied.  In truth, it really brings more questions left to be answered.

All eyes will be on the results of the clinical trials at the Mayo Clinic, Massachusetts General Hospital and University of Massachusetts Memorial Medical Center that will use the same treatment with the exact same protocol.  The more patients involved, the more accurate the results will be.  These phase 2 clinical trials will show the safety of the treatment, what type of patients might use this treatment, what dosage and how frequent it should be given.  If those treatments show positive outcomes, the treatment will proceed to Phase 3 clinical trials.  

The news is an important step forward in the right direction.  This kind of step infuses the whole scientific and medical community with energy to keep going.  All those other investigators, who are looking at ALS treatments using different methods, will not stop their work either.  A multi-faceted approach to dealing with ALS is coming.

Details on the NEALS-sponsored BrainStorm trial of implanted NTF-MSCs can be found here:https://clinicaltrials.gov/ct2/show/study/NCT02017912

Information about clinical trials, can be found at http://www.alsconsortium.org/browse.php or  https://clinicaltrials.gov/.

About the Author:

Seth Christensen
Seth is an ALS patient and founder of ALS Crowd, a division of the CrowdCare Foundation. As host of the ALS Crowd Radio show, he interviews top ALS researchers and focuses his efforts on the aggregation of big data to help researchers and patients find clues that will drive to a cure.
More Articles

ALS Crowd In the News ALS Crowd News

Haircuts & Hot Rods–Salt Lake City Car Show to Benefit ALSCrowd

The 1st annual Blues Barbershop Car Show will take place on September 19at Holladay City Hall  (2300 E. 4650 S. in Salt Lake City) with all proceeds benefiting ALS Crowd. The event will include t-shirt sales, live music (including Ryan Innes from NBC’s The Voice), concessions, family activities, and new and classic cars. Sponsors are invited to co-brand merchandise, […]

Life with ALS

Adaptive Ski Day

The National Ability Center in Park City, Utah is a place where many people have their best day ever.  This center is a global leader for adaptive recreation, serving individuals with a wide range of disabilities.  The National Ability Center empowers individuals of all abilities by building self-esteem, confidence and lifetime skills through sport, recreation […]

Creative Design

Donec At Mauris Enims

Quisque ligulas ipsum, euismod atras vulputate iltricies etri elit. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos. Nulla nunc dui, tristique in semper vel, congue sed ligula. Nam dolor ligula, faucibus id sodales in, auctor fringilla libero. Pellentesque pellentesque tempor tellus eget hendrerit. Morbi id aliquam ligula. Aliquam id dui […]